Adiposity and Endothelin Receptor Function
Study Description
“Adiposity and Endothelin Receptor Function”
Elevated levels of ET-1 have been implicated in cardiovascular disease and some forms of hypertension. Due to the strong, positive correlation between obesity and hypertension, the present study will explore the contribution of adiposity in ETB receptor function and aim to elucidate if ETB receptor dysfunction is a major contributor to hypertension in obesity.
Location
Methods
Pharmaceutical medication involved
Patients and healthy individuals accepted
Drug - Candesartan
7 days of Candesartan (16mg/day)
Drug - Placebo
7 days of Placebo
Additional Information
Official Study Title
Adiposity and Endothelin Receptor Function
Clinical Trial ID
NCT03583866
ParticipAid ID
b4xxxb
